Master production and control records lack a statement of theoretical yield including the maximum and minimum percentages of theoretical yield beyond which investigation is required.
Inspection Record
RayzeBio, Inc — FDA 483 Findings
Inspectors Muna Algharibeh · Scott McGrewThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Equipment are not cleaned, maintained, sanitized or sterilized at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed.
Employees engaged in the manufacture, processing, packing and holding of a drug product lack the training required to perform their assigned functions.
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet to any of its specifications Specifically, A.
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Your firm failed to provide adequate system for cleaning and disinfecting the room and equipment to produce aseptic condition.
Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality.
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Laboratory records do not include complete records of any testing and standardization of laboratory reference standards.
Routine calibration of automatic and electronic equipment is not performed according to a written program designed to assure proper performance.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Fresenius Kabi Oncology Limited2023-10-10 · US FDASimilar to finding 6 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- Medi-Fare Drug Pharmaceutical Compounding LLC2025-06-06 · US FDASimilar to finding 6 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- SURETEC INNOVATIONS LLC2026-03-05 · US FDASimilar to finding 9 The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
- Premier Pharmacy Labs, Inc.2015-07-11 · US FDASimilar to finding 3 Procedures designed to prevent microbiological contamination of d.tug products purporting to be sterile are not established, written, and followed .
- Eugia Pharma Specialities Limited2026-02-27 · US FDASimilar to finding 3 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed .
A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.